These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 30185703)

  • 1. [Thrombosis in myeloproliferative neoplasms].
    Asakura H
    Rinsho Ketsueki; 2018; 59(8):1034-1041. PubMed ID: 30185703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.
    Reikvam H; Tiu RV
    Leukemia; 2012 Apr; 26(4):563-71. PubMed ID: 22076463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombosis among 1537 patients with JAK2
    Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
    Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
    J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Sankar K; Stein BL; Rampal RK
    Cancer Treat Res; 2019; 179():159-178. PubMed ID: 31317487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis.
    Nagaharu K; Ohya E; Edahiro Y; Hashimoto Y; Ito T; Gotoh A; Nakamae M; Kimura F; Koike M; Kirito K; Wada H; Usuki K; Tanaka T; Mori T; Wakita S; Saito TI; Saito AM; Shimoda K; Kurokawa T; Tomita A; Kiyoi H; Akashi K; Matsumura I; Takenaka K; Komatsu N; Ohishi K; Tawara I; Sugimoto Y
    Ann Hematol; 2024 Sep; 103(9):3535-3541. PubMed ID: 39037588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology.
    Garrote M; López-Guerra M; García-Pagán JC; Arellano-Rodrigo E; Ferrer-Marín F; Hernández-Boluda JC; Bellosillo B; Nomdedeu M; Hernández-Gea V; Triguero A; Guijarro F; Álamo J; Baiges A; Turon F; Colomer D; Cervantes F; Alvarez-Larrán A
    Ann Hematol; 2024 Mar; 103(3):737-747. PubMed ID: 38263537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [State-of-the-art management for essential thrombocythemia and polycythemia vera].
    Sugimoto Y
    Rinsho Ketsueki; 2021; 62(8):1050-1059. PubMed ID: 34497191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
    Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
    Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
    Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.
    De Stefano V; Fiorini A; Rossi E; Za T; Farina G; Chiusolo P; Sica S; Leone G
    J Thromb Haemost; 2007 Apr; 5(4):708-14. PubMed ID: 17263783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera.
    Rottenstreich A; Kleinstern G; Krichevsky S; Varon D; Lavie D; Kalish Y
    Eur J Intern Med; 2017 Jun; 41():49-54. PubMed ID: 27919526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular landscape of myeloproliferative neoplasms associated with splanchnic vein thrombosis: Current perspective.
    Pescia C; Lopez G; Cattaneo D; Bucelli C; Gianelli U; Iurlo A
    Leuk Res; 2024 Jan; 136():107420. PubMed ID: 38016412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.